Probiotics in the treatment of Japanese cedar pollinosis: A double-blind placebo-controlled trial

Clinical and Experimental Allergy

Volumn 36, Issue 11, 2006, Pages 1425-1435

  Xiao, J Z ^a   Kondo, S ^a   Yanagisawa, N ^a   Takahashi, N ^a   Odamaki, T ^a   Iwabuchi, N ^a   Miyaji, K ^a   Iwatsuki, K ^a   Togashi, H ^b   Enomoto, K ^c   Enomoto, T ^d  

^a MORINAGA MILK INDUSTRY CO LTD   (Japan)

^b Togashi Clinic   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Allergy; Bifidobacterium longum; Cytokine; Eosinophil; Japanese cedar pollinosis; Probiotic; Thymus and activation regulated chemokine (TARC)

Indexed keywords

CHEMOKINE; PROBIOTIC AGENT;

ADULT; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM; BLOOD SAMPLING; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISPERSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE CEDAR; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; NOSE OBSTRUCTION; POLLEN; POLLEN ALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SEASON; SELF CARE; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; TH2 CELL; THYMUS;

ADULT; ANTIBODIES; BIFIDOBACTERIUM; BIOLOGICAL MARKERS; CHEMOKINES, CC; CRYPTOMERIA; CYTOKINES; DOUBLE-BLIND METHOD; EOSINOPHILIA; FEMALE; HUMANS; IMMUNOGLOBULIN E; INTERFERON TYPE II; INTERLEUKIN-10; MALE; PROBIOTICS; QUESTIONNAIRES; RHINITIS, ALLERGIC, SEASONAL; STATISTICS, NONPARAMETRIC; TH1 CELLS; TH2 CELLS;

EID: 33750550865     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2006.02575.x     Document Type: Article

References (38)

1. Enomoto T. Reevaluation of hygiene theory. Arerugi 2004; 53:465-8.
2. Bjorksten B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999; 108:342-6.
3. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001; 108:516-20.
4. Guidelines for the Evaluation of Probiotics in Food, Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, London Ontario, Canada, 2002. http://www.who.int/foodsafety/ fs_management/en/probiotic_guidelines.pdf
5. Matsuzaki T, Yamazaki R, Hashimoto S, Yokokura T. The effect of oral feeding of Lactobacillus casei strain Shirota on immunoglobulin E production in mice. J Dairy Sci 1998; 81:48-53.
6. Ishida Y, Bandou I, Kanzato H, Yamamoto N. Decrease in ovalbumin specific IgE of mice serum after oral uptake of lactic acid bacteria. Biosci Biochem Biotech 2003; 67:952-7.
7. Fujiwara D, Inoue S, Wakabayashi H, Fujii T. The anti-allergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance. Int Arch Allergy Immunol 2004; 135:205-15.
8. Kimoto H, Mizumachi K, Okamoto T, Kurisaki J. New Lactococcus strain with immunomodulatory activity: enhancement of Th1-type immune response. Microbiol Immunol 2004; 48:75-82.
9. Ohno H, Tsunemine S, Isa Y, Shimakawa M, Yamamura H. Oral administration of Bifidobacterium bifidum G9-1 suppresses total and antigen specific immunoglobulin E production in mice. Biol Pharm Bull 2005; 28:1462-6.
10. Hessle C, Hanson LA, Wold AE. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin Exp Immunol 1999; 116:276-82.
11. Niers LE, Timmerman HM, Rijkers GT et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy 2005; 35:1481-9.
12. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357:1076-9.
13. Viljanen M, Savilahti E, Haahtela T et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60:494-500.
14. Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol 2004; 5:152-8.
15. Ishida Y, Nakamura F, Kanzato H et al. Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study. J Dairy Sci 2005; 88:527-33.
16. Peng GC, Hsu CH. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr Allergy Immunol 2005; 16:433-8.
17. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99:179-85.
18. Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy 2002; 57:243-6.
19. Xiao JZ, Kondo S, Yanagisawa N et al. Effect of Probiotic Bifidobacterium longum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season, a randomized, double-blind, placebo-controlled trial. J Invest Allergol Clin Immunol 2006; 16:86-93.
20. Yamazaki S, Machii S, Tsuyuki S, Kawashima T, Ueda K. Immunological responses to monoassociated Bifidobacterium longum and their relations to prevention of invasion. Immunology 1985; 56:43-56.
21. Ishibashi N, Yaeshima T, Hayasawa H. Bifidobacteria: their significance in human intestinal health. Mal J Nutr 1997; 3:149-59.
22. Viljanen M, Pohjavuori E, Haahtela T et al. Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome. J Allergy Clin Immunol 2005; 115:1254-9.
23. Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O. Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J Biol Chem 1996; 271:21514-21.
24. Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 1997; 272:15036-42.
25. Locati M, Bonecchi R, Corsi MM. Chemokines and their receptors: roles in specific clinical conditions and measurement in the clinical laboratory. Am J Clin Pathol 2005; 123:S82-95.
26. Bonecchi R, Bianchi G, Bordignon PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187:129-34.
27. Ritter M, Goggel R, Chaudhary N et al. Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette smoke-induced pulmonary inflammation. Biochem Biophys Res Commun 2005; 334:254-62.
28. Okamoto H, Kamatani N. Plasma concentration of TARC/CCL17 is elevated in nonepisodic angioedema associated with eosinophilia. Allergy 2005; 60:1091-2.
29. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005; 60:685-8.
30. Hijnen D, De Bruin-Weller M, Oosting B et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004; 113:334-40.
31. Sugawara N, Yamashita T, Ote Y, Miura M, Terada N, Kurosawa M. TARC in allergic disease. Allergy 2002; 57:180-1.
32. Stavnezer J. Immunoglobulin class switching. Curr Opin Immunol 1996; 8:199-205.
33. Humbles AA, Lloyd CM, McMillan SJ et al. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305:1776-9.
34. Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-36.
35. Pessi T, Sutas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy 2000; 30:1804-8.
36. Laouini D, Alenius H, Bryce P, Oettgen H, Tsitsikov E, Geha RS. IL-10 is critical for Th2 responses in a murine model of allergic dermatitis. J Clin Invest 2000; 112:1058-66.
37. Zemann B, Schwaerzler C, Griot-Wenk M et al. Oral administration of specific antigens to allergy-prone infant dogs induces IL-10 and TGF-beta expression and prevents allergy in adult life. J Allergy Clin Immunol 2003; 111:1069-75.
38. Faria AM, Maron R, Ficker SM, Slavin AJ, Spahn T, Weiner HL. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J Autoimmun 2003; 20:35-45.